Business Context and Reporting Period
This Form 8-K, dated February 2, 2021, reports on Veracyte, Inc.'s entry into a definitive merger agreement to acquire Decipher Biosciences, Inc., a precision oncology company focused on prostate and bladder cancers. The filing also includes preliminary, unaudited financial results for Veracyte and Decipher for the fourth quarter and full year ended December 31, 2020.
Key Financial Metrics
Veracyte, Inc. (Preliminary/Unaudited)
- Q4 2020 Revenue: Estimated between $34.0 million and $35.0 million.
- Full Year 2020 Revenue: Estimated between $117.0 million and $118.0 million.
- Q4 2020 Testing Volume: Between 13,000 and 13,200 tests.
- Full Year 2020 Testing Volume: Between 44,400 and 44,600 tests.
- Cash and Cash Equivalents (as of Dec 31, 2020): Estimated between $345.0 million and $350.0 million.
- Profit/Margins: The filing text does not provide a clear value for net income, gross margin, or operating margin.
Decipher Biosciences (Target)
- 2019 Revenue: $16.5 million.
- 2018 Revenue: $12.1 million.
- Q4 2020 Revenue (Preliminary): Estimated between $39.0 million and $40.0 million.
- 2020 Genomic Testing Volume (Preliminary): Between 15,500 and 16,500 tests.
Material Changes and Transaction Details
Veracyte entered into an Agreement and Plan of Merger to acquire Decipher Biosciences for a total consideration of $600 million. The consideration structure includes:
- Cash: $250 million.
- Stock: $350 million, calculated at an agreed price of $54.30 per share (maximum issuance of 6.4 million shares).
- Flexibility: Veracyte retains the option to substitute cash for the entire stock portion of the consideration until March 15, 2021.
The transaction is anticipated to close by May 2021, subject to customary conditions including Decipher stockholder approval and regulatory clearance. Stockholder agreements have been signed by holders representing approximately 73% of Decipher's outstanding capital stock to vote in favor of the merger.
Management Changes
Tina S. Nova, Ph.D., CEO of Decipher and former Veracyte board member, resigned from the Veracyte board on February 2, 2021, to avoid conflicts of interest. Upon closing, she is expected to serve as the general manager for Veracyte's urologic cancers business unit. Robert S. Epstein, MD MS, serves on both boards and recused himself from negotiations.
Guidance, Outlook, and Risks
Management expects the acquisition to accelerate Veracyte's revenue growth and path to profitability, expand the total addressable market, and be accretive to gross margins. The integration aims to broaden product offerings in cancer diagnostics and utilize Decipher's GRID platform to augment biorepositories.
Risks and Contingencies:
- Transaction Risks: Failure to satisfy closing conditions, regulatory approvals, or stockholder litigation could delay or prevent the merger.
- Integration Risks: Challenges in retaining Decipher employees and achieving anticipated synergies.
- Financial Uncertainty: The preliminary revenue and cash figures for both companies are unaudited and subject to adjustment upon final audit.
- External Factors: The COVID-19 pandemic poses significant economic uncertainty and operational risks.
Investor Verification Checklist
- Verify the final audited financial statements for Veracyte and Decipher for the year ended December 31, 2020, as current figures are preliminary estimates.
- Monitor the filing of the Form S-4 Registration Statement for the full terms of the Merger Agreement and the prospectus.
- Confirm the outcome of the Decipher stockholder vote and the expiration of the Hart-Scott-Rodino waiting period.
- Assess the final mix of cash versus stock consideration, as Veracyte may elect to pay the full $350 million stock portion in cash.
- Review the "Risk Factors" in Veracyte's most recent Form 10-K and 10-Q for detailed disclosures on business risks.